Oncotarget is an open access, peer-reviewed medical journal that specializes in the pathological basis of cancers, as well as improving treatments and therapy for cancer patients. The journal is also dedicated to research on enhancing the quality of life and treatment procedures for patients (https://www.dovepress.com/oncotargets-and-therapy-journal). Because Oncotarget is open access, it is free to the public to look up and read, and they even offer to print in exceptional situations. The journal employs distinguished scientists and medical professionals such as Mikhail Blagoskionny, many of whom have published multiple works on the advancement of medicine and medical treatments. Visit ResearchGate.Net to know more about Mikhail’s latest work.
Oncotarget derives from the term “oncology,” which is the study and treatment of tumors both malignant and benign. Many of the articles published through this esteemed journal focus on the causes and implications of tumors that are cancerous in nature, although the success of the journal has invited a wider range of articles over a broad spectrum of topics such as neuroscience, cell biology, cardiology, and various pharmaceutical areas. (http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget). The medical journal is peer-reviewed by a team of highly trained professionals and doctors who are experts in the field, such as Dr. Blagoskionny, who serves as the editor in chief alongside Dr. Andrei Gudkov.
Mikhail Blagosklonny has both an M.D. and a Ph. D. in medicine and cardiology, and is currently a medical professor of oncology at the Rosewell Park Cancer Institute. He has published numerous medical papers and medical journals, totaling over 250 publications and 25, 000 citations. His works focus on oncology, as well as the aging process and how to use certain cancer-fighting drugs such as rapamycin to increase the average lifespan. Facts
As of 2016, Oncotarget had an impact factor of 5.008, with over 10,000 citations to works published. This number is expected to rise through 2017 and beyond, especially with new technologies and research coming into the field. In five years time, Oncotarget is projected to reach an impact factor of 5.415. In 2015, Oncotarget was highest ranked among all oncology peer-reviewed journals and remains one of the top scholarly sources for open access medical news and advancement. View Mikhail’s profile on Google Scholar